MEN1 and leukemia: In 2012, the first potent and selective Menin–KMT2A interaction inhibitor, MI2‐2, was discovered, showing activity in reducing cellular proliferation and oncogenic gene expression in KMT2A‐rearranged leukemia.95, 101